Similar articles

• Prostatic artery embolization to treat lower urinary tract symptoms related to benign prostatic hyperplasia and bleeding in patients with prostate cancer: proceedings from a multidisciplinary research consensus panel.

  Golzarian J, Antunes AA, Bilhim T, Carnevale FC, Konety B, McVary KT, Parsons JK, Pisco JM, Siegel DN, Spies J, Wasserman N, Gowda N, Ahrar K. Golzarian J, et al. J Vasc Interv Radiol. 2014 May;25(5):665-74. doi: 10.1016/j.jvir.2013.11.003. Epub 2014 Feb 21. J Vasc Interv Radiol. 2014. PMID: 24560898 No abstract available.
• Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.

  Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, Lowe F, O'Leary M, Perez M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Speakman M, et al. Prostate Cancer Prostatic Dis. 2005;8(4):369-74. doi: 10.1038/sj.pcan.4500827. Prostate Cancer Prostatic Dis. 2005. PMID: 16130013
• Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms.

  Parsons JK. Parsons JK. Curr Opin Urol. 2011 Jan;21(1):1-4. doi: 10.1097/MOU.0b013e32834100c9. Curr Opin Urol. 2011. PMID: 21045705 Review.
• Injectables in the prostate.

  Saemi AM, Plante MK. Saemi AM, et al. Curr Opin Urol. 2008 Jan;18(1):28-33. doi: 10.1097/MOU.0b013e3282f20169. Curr Opin Urol. 2008. PMID: 18090486 Review.
• Re: Nakai H, Yamanishi T, Yasuda K, Kitahara S, Suzuki T. 2004. Correlation between lower urinary tract symptoms and urethral function in benign prostatic hyperplasia.

  Schaefer W. Schaefer W. Neurourol Urodyn. 2006;25(1):99-100. doi: 10.1002/nau.20137. Neurourol Urodyn. 2006. PMID: 16178001 No abstract available.